Inhibitors of MCT1 in tumor cells have been shown to effectively inhibit lipid synthesis in cancer cells and increase influx of tumor immune cells, and some of these inhibitors are currently being tested in clinical trials [133]. The gene discussed is SLC16A1; the disease is neoplasm.